Repository logo
 
No Thumbnail Available
Publication

Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer

Use this identifier to reference this record.

Advisor(s)

Abstract(s)

Imatinib mesylate is a chemotherapeutic drug that inhibits the tyrosine kinase activity of c-KIT and has been successfully used to treat leukemias and some solid tumors. However, its application for treatment of hormone-refractory prostate cancer (HRPC) has shown modest effectiveness and did not follow the outcomes in cultured cells or animal models. Moreover, the molecular pathways by which imatinib induces cytotoxicity in prostate cancer cells are poorly characterized.

Description

Keywords

c-KIT DU14 Hormone-refractory prostate cancer Imatinib PC3 Prostate cancer cells

Citation

Research Projects

Research ProjectShow more

Organizational Units

Journal Issue